Sulindac exhibits anti-proliferative and anti-invasive effects in uterine serous carcinoma cells.

ABSTRACT:

Purpose

Uterine serous carcinoma (USC) is a highly aggressive and frequently recurring subtype of endometrial cancer with limited treatment options for advanced or recurrent stages. Sulindac, a classic non-steroidal anti-inflammatory drug, has demonstrated anti-tumor activity in several pre-clinical tumor models. This study aims to evaluate the effect of sulindac on cell proliferation and invasion in USC cells.

Methods

Human USC cell lines ARK-1 and SPEC2 were treated with different concentrations of sulindac. Cell proliferation was assessed using MTT and colony formation assays. ELISA assays measured cellular stress, cleaved caspase 3 activity, antioxidant ability, and adhesion. Cell cycle arrest was evaluated by Cellometer. The invasive capability was detected by wound hea

SUBMITTER: Chen S 

PROVIDER: S-EPMC11358172 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature